Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/11/2025

Treatment of Membranous Nephropathy

Initial Treatment

  • For patients with membranous nephropathy and at least one risk factor for disease progression, the Kidney International guideline recommends rituximab or cyclophosphamide with alternate month glucocorticoids for 6 months, or tacrolimus-based therapy for ≥6 months as initial treatment, with the choice depending on the risk estimate and eGFR status 1
  • Immunosuppressive therapy is not required in patients with proteinuria <3.5 g/day, serum albumin >30 g/L, and eGFR >60 mL/min/1.73m² 1
  • The Kidney International guidelines and the American Journal of Kidney Diseases guidelines recommend immunosuppression in patients with persistent proteinuria >4 g/day despite 6 months of supportive care, severe, disabling, or life-threatening symptoms related to nephrotic syndrome, or serum creatinine rise ≥30% within 6-12 months (with eGFR >30 ml/min/1.73m²), based on moderate-quality evidence 1, 2, 3

Treatment Options

  • For patients with stable eGFR, the first choice is rituximab, with dosing of two weekly infusions of 375 mg/m² or two infusions of 1g each given 2 weeks apart 1
  • For patients with declining eGFR, the first choice is cyclophosphamide with glucocorticoids, with a maximum cumulative dose of 36g and a maximum of 10g if fertility preservation is needed 1
  • Tacrolimus-based therapy for ≥6 months is an alternative option for both stable or declining eGFR, with regular monitoring of blood levels and watch for nephrotoxicity 1, 4
  • Cyclophosphamide dosing limitations include a maximum cumulative dose of 36g and a maximum of 10g if preservation of fertility is required, as per the Kidney International guidelines 1
  • Mycophenolate mofetil (MMF) is not recommended as monotherapy for initial treatment of MN, with limited evidence for resistant cases, as stated by the Kidney International guidelines 5

Treatment Response and Resistance

  • Response to therapy usually occurs within 3 months after starting therapy 1
  • Before declaring treatment resistance, patient compliance, B-cell response, anti-rituximab antibodies, IgG levels, leukocytopenia during cyclophosphamide, and CNI blood levels should be checked 1
  • Consider secondary focal segmental glomerulosclerosis (FSGS) if anti-PLA2R antibodies have disappeared but proteinuria persists 1
  • Persistence of proteinuria for 12-24 months after disappearance of anti-PLA2R antibodies is expected and does not constitute resistant disease, as stated by the American Journal of Kidney Diseases 6
  • For patients who fail both rituximab and cyclophosphamide, referral to specialized glomerulonephritis centers is recommended, and experimental therapies may be considered, such as second-generation anti-CD20 agents, anti-CD38 therapy, proteasome inhibitors, and belimumab, as stated by the American Journal of Kidney Diseases 6

Supportive Care

  • All patients with primary MN and proteinuria should receive optimal supportive care 1
  • The Kidney International guideline recommends considering prophylactic anticoagulation in patients with serum albumin <25 g/L (by bromocresol purple) or <20 g/L (by bromocresol green), or additional risk factors for thrombosis 1
  • The American Journal of Kidney Diseases guidelines also highlight the importance of thromboprophylaxis in high-risk patients with severe hypoalbuminemia, based on low-quality evidence 2
  • Clinical parameters such as proteinuria and serum albumin should be evaluated regularly, with clinical remission may taking 12-18 months to achieve, and eGFR should be monitored for stability 1
  • Anti-PLA2R antibody levels should be monitored every 3 months, with immunological remission typically preceding clinical remission, and response usually occurring within 3 months after starting therapy, as recommended by the Kidney International guidelines 1

Special Considerations

  • The American Journal of Kidney Diseases guidelines recommend against immunosuppression in patients with serum creatinine persistently ≥3.5 mg/dL or eGFR ≤30 ml/min/1.73m², reduced kidney size on ultrasound, or severe or potentially life-threatening infections 3
  • Consultation with an expert center is recommended for patients with declining eGFR, as stated by the Kidney International guidelines 1
  • The strength of evidence for the indications for immunosuppression is based on moderate-quality evidence, according to the American Journal of Kidney Diseases guidelines 3
  • The Kidney International guidelines recommend rituximab as a preferred treatment option in younger patients or those concerned about fertility, based on high-quality evidence 1
  • Cyclophosphamide with alternate month glucocorticoids for 6 months is also a recommended treatment option, based on moderate-quality evidence 1
  • Calcineurin inhibitors (tacrolimus or cyclosporine) for ≥6-12 months may be considered as an alternative treatment option, based on low-quality evidence 1